Physician profile
Benjamin D Sage
NPI 1134520281
$956.27
in general payments reported to CMS, 2019-2025
14 companies · $15.65 in 2025
The $15.65 reported for 2025 was less than what a typical Physician Assistant provider received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $520 · 2024: $421 · 2025: $15.65.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $956.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $956.27 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $286.98 | 2023-2024 | Ozempic, Rybelsus, Wegovy |
| Abbott Laboratories | $177.59 | 2024 | Freestyle Libre 3 |
| Boehringer Ingelheim Pharmaceuticals, INC. | $141.82 | 2023 | Jardiance, Tradjenta |
| Lilly USA, LLC | $53.54 | 2023 | Mounjaro, Emgality, Jardiance |
| Xeris Pharmaceuticals, INC. | $48.42 | 2023 | Gvoke Hypopen, Keveyis |
| Abbvie INC. | $46.81 | 2023 | |
| Astellas Pharma US INC | $41.40 | 2023-2024 | Veozah |
| Amgen INC. | $33.50 | 2024 | Evenity, Prolia, Repatha |
| Glaxosmithkline, LLC. | $29.15 | 2024-2025 | Shingrix, Trelegy Ellipta |
| Axsome Therapeutics, INC. | $29.13 | 2023 | Auvelity |
| Organon LLC | $18.36 | 2024 | |
| Collegium Pharmaceutical, INC. | $17.41 | 2024 | Belbuca |
| Dynavax Technologies Corporation | $16.76 | 2023 | Heplisav-B |
| Astrazeneca Pharmaceuticals LP | $15.40 | 2023 | Farxiga |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Benjamin Sage listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.